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OBJECTIVE — To investigate diabetes-speciﬁc autoantibodies and additional autoimmune
phenomena in a large cohort of young patients with type 1 diabetes.
RESEARCH DESIGN AND METHODS — Data from 28,671 patients 30 years with
type 1 diabetes from 242 specialized centers in Germany and Austria were analyzed.
RESULTS — At least one -cell antibody was present in 81.6% of patients. -cell–Ab-
negativepatientsweresigniﬁcantlyyoungeratdiabetesonset(P  0.0001).Atotalof19.6%
had positive thyroid antibodies with female predominance (62%, P  0.0001). Antibodies
to tissue transglutaminase were present in 10.7%, with a signiﬁcantly longer duration of
diabetes (P  0.0001). Parietal cell antibodies were found in 283 patients, associated with
older age (P  0.001), and adrenal antibodies were present in 94 patients. In 575 patients,
at least three different autoimmune phenomena were present.
CONCLUSIONS — Thyroid autoimmunity and antibodies suggestive for celiac disease are the
most prevalent additional immune phenomena in type 1 diabetes. Parietal/adrenal antibodies are rare.
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A
dditional autoimmune phenomena
such as Hashimoto thyroiditis or
celiac disease are a frequent obser-
vation in type 1 diabetes (1,2). The ap-
pearance of autoantibodies is often the
ﬁrst detectable sign of autoimmune dis-
eases (3). The aim of this study was to
investigate screening frequency and prev-
alence of autoimmune phenomena in a
large cohort of children, adolescents, and
young adults with type 1 diabetes.
RESEARCH DESIGN AND
METHODS
Data collection
Data were collected from 242 depart-
ments in Germany/Austria by means of
a computerized follow-up program
called the Diabetes Prospective Docu-
mentation Initiative (Diabetes Patienten
Verlaufsdokumentation [DPV]) (4).
Patient characteristics
Data from 46,342 patients between 1990
and 2008 were included in the database.
We analyzed 28,671 patients (mean age
13.7years;range0–30;52.2%male)with
at least one autoantibody measurement
(GADA, ICA, IAA, and IA-2A at onset;
TG, TPO, Gliadin-Ab, TGA, PCA, and
AA-Ab). Patients were divided into age-
groupsaccordingtodevelopmentalstage:
age-group 1 (0.1–12 years; n  9,431),
age-group 2 (12–18 years; n  15,495),
and age-group 3 (18–30 years; n 
3,745).
Statistical analysis
Data were analyzed using the SAS statis-
tical software package, version 9.1 (SAS
Institute, Cary, NC). Data are presented
asmeanSDfornormaldistributedvari-
ables or median and range for non-
Gaussian distributed parameters. For
group comparisons, nonparametric sta-
tistical tests (Kruskall-Wallis test) were
used, with adjustment for multiple com-
parisons (method of Holm). Differences
of frequencies for categorical variables
were tested by the 
2 test. A P value
0.05 was considered as statistically
signiﬁcant.
RESULTS
Screening frequency
Thyroid autoantibodies were screened in
87.3% of patients, followed by celiac dis-
ease antibody (75.7%), TGA (49.9%),
-cell–Ab (52.6%), AA-Ab (10.0%), and
PCA (6.3%); all listed in Table 1.
-Cell autoimmunity
At least one -cell–Ab (ICA, GAD, IA2,
IAA) was present in 12,070 of 14,784 pa-
tients (81.6%). GADAs were most fre-
quently measured (n  11,150, 65.3%
positive), followed by ICAs (n  10,515,
58.3% positive), IAAs (n  8,468, 67.6%
positive), and IA-2As (n  7,488, 66.1%
positive). -Cell–AB-negative patients
were signiﬁcantly younger at type 1 dia-
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P  0.0001).
Thyroid autoimmunity
A total of 4,901 patients (19.6%) were
foundtohaveelevatedtitersofatleastone
thyroid Ab. Thyroid autoimmunity was
associated to female sex (62 vs. 44% in
thyroid-Ab–negative patients, P 
0.0001),olderage(15.33.8vs.13.4
4.6 years), and longer duration of diabe-
tes (6.7  4.5 vs. 5.3  4.1 years; both P
 0.0001).
Celiac disease autoimmunity
TGAs were measured in 14,301 patients,
with a positive result in 10.7% (n 
1,529). TGA-positive patients showed a
signiﬁcantly longer duration of diabetes
(5.6  3.9 vs. 5.0  3.9 years, P 
0.0001).
Parietal cell autoimmunity
PCAs were investigated in 1,795 patients
(6.3%), with a positive result in 283 sub-
jects (15.8%), associated with older age
(15.8  4.7 vs. 14.3  4.6 years, P 
0.001) and longer duration of diabetes
(8.3 vs. 6.1 years, P  0.0001).
Anti-adrenal autoimmunity
Screening for AA-Ab was performed in
2,877 patients (10.0%), with a positive
result in 94 patients (3.3%). This group
did not differ clinically from patients
withoutAA-Ab.Patientswith-cellauto-
immunity showed a signiﬁcantly higher
prevalence of AA-Ab compared with
-cell–Ab-negative patients (3.7 vs.
1.5%, P  0.05).
Patients with three or more
autoimmune phenomena
In 575 patients (60% female, mean age
14.4 years), at least three different auto-
immune phenomena were present (most
prevalent: -cell–Ab, n  565; TPO, n 
378). Four organ systems were involved
in 46 patients.
CONCLUSIONS— We present the
results of a large patient group based on
the DPV documentation system. This in-
volved the participation of 242 diabetes
centers, 28,671 documented patients,
and an observation period 10 years.
As previously shown, -cell antibod-
ies were present in 80% of patients di-
agnosed with type 1 diabetes (5). The
observation that -cell–Ab-negative sub-
jects were younger is not consistent with
previous ﬁndings, suggesting -cell–Ab-
negative diabetes forms at an older age in
a cohort of patients 18 years, but this
might have been also patients with clini-
cal type 2 diabetes (6).
Our data support previous studies
documenting the high prevalence of thy-
roidautoimmunityinyoungpatientswith
type1diabetes(7)andtheirassociationto
female sex and older age (8).
We can show an association between
autoimmunity suggestive of celiac disease
and a longer duration of type 1 diabetes.
The hypothesis of type 1 diabetes as the
ﬁrst autoimmune disease, followed by ce-
liac disease (9,10), is conﬁrmed and em-
phasizes the need for repeated antibody
testing for celiac disease.
PCAs are characteristic for autoim-
mune gastritis and are directed to the
H,K-ATPase of parietal cells. This is
the ﬁrst study to investigate PCAs in a
large cohort of young patients with type 1
diabetes. The prevalence of PCAs in-
creased with age and longer duration of
type 1 diabetes.
In a study of adults with type 1 dia-
betes,DeBlocketal.(11)reportedaprev-
alence of 20.9% of patients with PCA,
withirondeﬁciencyanemiain15.4%and
pernicious anemia in 10.5%.
Tests for AA-Abs were performed in
10%(3%positive).Barkeretal.(12)stud-
iedAA-Abinpatientswithtype1diabetes
in 2005 with a positive result in 1.4%. In
previous studies, the development of Ad-
dison’s disease in patients with AA-Ab
varies between 18 and 45% (13,14).
Unfortunately, we do not have data
on the reasons for PCA and AA-Ab test-
ing, nor do we know about clinical out-
come.Thus,theunexpectedhighnumber
of positive patients may be due to selec-
tion factors such as underlying disorders,
or even cost factors. Further studies on
prevalence of PCA and AA-Ab in type 1
diabetes and associated clinical features
are preferable.
Apart from a slightly higher preva-
lence of AA-Ab in the -cell–Ab-positive
groups, no differences between -cell–
Ab-positive and -negative patients were
detected. Thus, the proof of -cell auto-
immunitycannotbeseenasapredictorof
additional autoimmunity.
Multicenter studies on autoimmune
phenomena are under way. We are aware
oftheweaknessofdecentralizedantibody
testing, but centralized measurements
were not practicable because of organiza-
tional/ﬁnancial difﬁculties and the in-
volvement of 242 centers. Nevertheless,
they reﬂect the situation with which cli-
nicians are dealing. All of the laboratories
have taken part at a nationwide quality
control circle and gave consent to inter-
national standardization workshops (15).
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Table 1—Screening frequency and number of patients with positive autoantibodies (in paren-
theses) in 28,671 patients with type 1 diabetes (divided into three age-groups) from the
German-Austrian DPV-Wiss cohort
12 years 12–18 years 18–30 years
N 9,431 15,495 3,745
-Cell–Ab 5,622 (84.1) 7,414 (81.4) 1,748 (74.5)
GADA 4,710 (63.5) 5,380 (66.6) 1,060 (67.5)
ICA 3,855 (58.4) 5,331 (59.0) 1,329 (55.6)
IA-2A 3,148 (67.8) 3,609 (66.4) 731 (57.3)
IAA 3,145 (66.2) 4,373 (68.1) 1,027 (72.0)
Thyroid-Ab† 8,023 (11.4) 13,791 (22.6) 3,232 (26.9)
TPO 7,874 (8.8) 13,547 (18.6) 3,142 (20.5)
TG 5,713 (9.3) 10,291 (16.6) 2,750 (21.4)
CD-Ab‡ 7,512 (20.7) 11,693 (21.0) 2,504 (19.2)
Gliadin-IgA 5,520 (6.9) 9,378 (6.8) 2,220 (6.6)
Gliadin-IgG 4,796 (20.2) 8,098 (18.1) 1,749 (14.5)
TGA 5,557 (10.1) 7,599 (10.7) 1,145 (13.0)
PCA 494 (11.1) 949 (15.6) 352 (22.7)
AA-Ab 764 (3.0) 1,588 (3.3) 525 (3.6)
*Data are n (% positive) (n refers to the number of patients with at least one autoantibody determination).
†Thyroid-Ab includes antibodies against thyreoperoxidase and against thyreoglobulin. ‡CD-Ab includes
autoantibodies against Gliadin (IgA/ IgG) and anti-tissue transglutaminase.
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